All publications
Veterinary soft chews using Gelucire® 50/13 and Precirol® ATO 5. A proof of concept with wet extrusion
ECP - Mar 2025
This study aims to demonstrate the effectiveness of Gelucire® 50/13, a surfactant, and Precirol® ATO 5, a taste-masking agent, in producing veterinary soft chews using a wet extrusion process. These ingredients enable the development of high-drug load formulations with taste-masking capabilities and customizable drug release profiles, making them ideal for this innovative dosage form.
In Vitro In Silico Correlation of Lidocaine HCl Skin Permeation - A Comparative Study of Gel Cream and Bigel formulations
ECP - Mar 2025
In this work, the effectiveness of Skin-in-Silico™ software for simulating dermal absorption and permeation of lidocaine hydrochloride in gel, cream, and bi-gel forms was evaluated. By combining in silico predictions with in vitro experiments, we explore the correlation between these methods and their role in optimizing topical drug formulations.
Advantages of combining cellulosic polymers and lipids in extruded 3D printing filaments - Part I
ECP - Mar 2025
This study explores the use of 3D printing, specifically fused deposition modeling (FDM), for personalized medicine by combining lipids and cellulosic excipients like hypromellose (HPMC). Hot-melt extrusion (HME) is employed to create filaments, with a focus on balancing processing temperatures and mechanical properties.
A QbD-based UPLC-ELSD method for quantifying medium-chain triglycerides in Labrafac™ WL 1349 for nanoemulsion applications
Molecules - Jan 2025
This article showcases the development and validation of a robust UPLC-ELSD method, using analytical Quality-by-Design principles, to accurately quantify medium-chain triglycerides in a lipid-based excipient for nanoemulsion applications, ensuring compliance with regulatory standards.
Understanding Microemulsions and Nanoemulsions in (Trans)Dermal Delivery
AAPS PharmSciTech - Jan 2025
Microemulsions and nanoemulsions are explored in pharmaceuticals for their potential in delivering clinically relevant drug doses across biological membranes. Despite extensive literature, there's a lack of clear distinctions between the two in terms of definitions and mechanisms: this review aims to uncover less obvious yet important mechanisms in transdermal drug delivery.
Bigels: case studies of an innovative topical dosage form
ABCF Congress - Nov 2024
Adherence to treatments is a key challenge for topical formulations. Bigels, formulated with Emulfree® Duo are an innovative dosage form that can combine both hydrophilic and lipophilic active ingredients in a stable, moisturizing, and easily spreadable formulation. This study showcases three different placebo bigels formulations.
Unveiling the Potential of Labrasol® ALF Labrafac™ MC60 and Capryol® 90 as Permeation Enhancers to Address Low Bioavailability Issues
American Pharmaceutical Review - Oct 2024
In vitro, ex vivo, and in vivo tests show that Labrasol® ALF, Labrafac™ MC60, and Capryol® 90 are effective and safe permeation enhancers. They work by temporarily opening tight junctions in the intestinal lining, potentially improving the bioavailability of poorly permeable drugs, including small molecules (BCS III and IV) and large molecules like peptides and proteins.
Platform technology for introducing liquid solubilizers in tablet formulations
AAPS - Oct 2024
Lipid-based excipients, which are often liquid at room temperature, can enhance solubility and permeation. This study aims to incorporate a liquid lipid excipient into a solid dosage form for the poorly water-soluble drug ondansetron hydrochloride dihydrate (OHD).
Toward improving the in vitro in vivo correlation of lipid-based formulations using a simplified gastro-intestinal lipolysis protocol
AAPS - Oct 2024
Lipid-based formulations (LBF) enhance the oral bioavailability of poorly water-soluble drugs by maintaining them in a solubilized state during digestion. This study aims to establish a robust protocol to evaluate the impact of gastro-intestinal lipolysis on LBF performance, using cinnarizine as a model drug.